Clinical Trials Logo

Refractory Mantle Cell Lymphoma clinical trials

View clinical trials related to Refractory Mantle Cell Lymphoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03579888 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

CD19-Specific T Cells Post AlloSCT

Start date: June 26, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic lymphocytic lymphoma. Sometimes researchers change the genetic material in the cells of a patient's T cells using a process called gene transfer. Researchers then inject the changed T-cells into the patient's body. Receiving the T-cell infusion may help to control the disease.

NCT ID: NCT02572453 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Start date: April 4, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment (refractory) or that has returned after a period of improvement (recurrent). Onalespib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02489123 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Start date: August 11, 2015
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgen made by the body.

NCT ID: NCT02420795 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: November 3, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to see how well it works in treating patients with non-Hodgkin's lymphoma that has returned after a period of improvement or does not respond to treatment. Akt/ERK inhibitor ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.